https://www.nasdaq.com/press-release/beam-therapeutics-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/beam-therapeutics-outlines-long-term-strategy-for-base-editing-programs-in-sickle
https://www.nasdaq.com/press-release/beam-therapeutics-reports-preclinical-data-highlighting-multiplex-base-editing
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-the-jefferies-2021-virtual-london-healthcare
https://www.nasdaq.com/press-release/beam-therapeutics-provides-business-and-pipeline-updates-and-reports-third-quarter
https://www.nasdaq.com/press-release/beam-therapeutics-appoints-healthcare-industry-leader-john-maraganore-ph.d.-to-its
https://www.nasdaq.com/press-release/beam-therapeutics-announces-upcoming-preclinical-data-presentations-at-the-american
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-the-jefferies-gene-therapy-editing-summit-2021-10
https://www.nasdaq.com/press-release/sana-biotechnology-obtains-a-non-exclusive-license-to-crispr-cas12b-gene-editing
https://www.nasdaq.com/press-release/beam-therapeutics-announces-preclinical-data-highlighting-base-editing-approach-to
https://www.nasdaq.com/press-release/beam-therapeutics-to-present-preclinical-data-highlighting-potential-of-car-t
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-the-chardan-virtual-5th-annual-genetic-medicines
https://www.nasdaq.com/press-release/beam-therapeutics-announces-preclinical-data-highlighting-potential-of-base-editors
https://www.nasdaq.com/press-release/beam-therapeutics-announces-updated-preclinical-data-highlighting-optimized-lnp
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-the-2021-wells-fargo-virtual-healthcare
https://www.nasdaq.com/press-release/beam-therapeutics-provides-business-and-pipeline-updates-and-reports-second-quarter
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-the-2021-wedbush-pacgrow-healthcare-conference
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-the-2021-william-blair-biotech-focus-conference
https://www.nasdaq.com/press-release/apellis-and-beam-therapeutics-enter-exclusive-research-collaboration-to-apply-base
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-the-2021-jefferies-virtual-healthcare-conference
https://www.nasdaq.com/press-release/beam-therapeutics-presents-lnp-formulation-data-at-asgct-and-reports-first-quarter
https://www.nasdaq.com/press-release/beam-therapeutics-announces-oral-and-poster-presentations-at-24th-american-society-of
https://www.nasdaq.com/press-release/beam-therapeutics-publishes-data-highlighting-ability-to-rationally-design-base
https://www.nasdaq.com/press-release/beam-therapeutics-announces-business-and-pipeline-progress-and-reports-fourth-quarter
https://www.nasdaq.com/press-release/beam-therapeutics-appoints-amy-simon-m.d.-chief-medical-officer-2021-03-15
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-the-barclays-2021-global-healthcare-conference
https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23
https://www.nasdaq.com/press-release/beam-therapeutics-inc.-announces-%24260-million-common-stock-investment-from-multiple
https://www.nasdaq.com/press-release/beam-therapeutics-appoints-leading-healthcare-executive-kate-walsh-to-its-board-of
https://www.nasdaq.com/press-release/beam-therapeutics-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/beam-therapeutics-presents-updated-data-from-novel-base-editing-programs-for-sickle
https://www.nasdaq.com/press-release/the-boston-globe-names-beam-therapeutics-a-top-place-to-work-for-2020-2020-11-20
https://www.nasdaq.com/press-release/beam-therapeutics-presents-first-data-highlighting-base-editing-program-for-glycogen
https://www.nasdaq.com/press-release/beam-therapeutics-announces-business-and-pipeline-progress-and-reports-third-quarter
https://www.nasdaq.com/press-release/beam-therapeutics-names-first-car-t-base-editing-development-candidate-for-the
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-chardan-virtual-4th-annual-genetic-medicines
https://www.nasdaq.com/press-release/beam-therapeutics-announces-pricing-of-public-offering-of-common-stock-2020-09-30
https://www.nasdaq.com/press-release/beam-therapeutics-announces-proposed-public-offering-of-common-stock-2020-09-28
https://www.nasdaq.com/press-release/beam-therapeutics-announces-first-development-candidates-for-sickle-cell-disease-and
https://www.nasdaq.com/press-release/beam-therapeutics-to-participate-in-upcoming-investor-conferences-2020-07-30
https://www.nasdaq.com/press-release/beam-therapeutics-to-present-at-jefferies-2020-virtual-healthcare-conference-2020-05
https://www.nasdaq.com/press-release/beam-therapeutics-reports-additional-data-at-asgct-annual-meeting-and-first-quarter
https://www.nasdaq.com/press-release/beam-therapeutics-to-present-updated-data-highlighting-base-editing-programs-for
https://www.nasdaq.com/press-release/beam-therapeutics-to-present-first-data-highlighting-base-editing-program-for-alpha-1
https://www.nasdaq.com/press-release/beam-therapeutics-reports-business-updates-and-full-year-2019-financial-results-2020
https://www.nasdaq.com/press-release/beam-therapeutics-announces-key-rd-appointments-2020-03-16
https://www.nasdaq.com/press-release/beam-therapeutics-announces-closing-of-initial-public-offering-2020-02-11
https://www.nasdaq.com/press-release/beam-therapeutics-announces-pricing-of-initial-public-offering-2020-02-11
